Clinical Trials on Secondary Prevention in Japan

Total 51 results

Kyowa Kirin Co., Ltd.

Completed

Phase 3 Study of KHK7580

Secondary Hyperparathyroidism

Japan
Kumamoto University

Completed

Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT)

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis

Secondary Hyperparathyroidism

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Phase 3 Study of SK-1403

Secondary Hyperparathyroidism

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase 3 Study of KHK7580

Secondary Hyperparathyroidism

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase 2 Study of KHK7580

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase 3 Study of KHK7580

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis

Hyperparathyroidism

Japan
Takeda

Withdrawn

A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult Participants

Influenza Prevention

Japan
Takeda

Completed

A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects

Pandemic Influenza Prevention

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis

Secondary Hyperparathyroidism

Japan
Daiichi Sankyo Co., Ltd.

Completed

A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty

Venous Thromboembolism | Prevention

Japan
Boehringer Ingelheim

Completed

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Stroke | Secondary Prevention

Korea, Republic of, United States, Spain, Canada, Germany, Taiwan, Belgium, Australia, Hong Kong, India, Singapore, Thailand, Greece, Italy, Japan, China, Turkey, Russian Federation, Serbia, Switzerland, Israel, South Africa, Malaysia, Fran... and more
Novartis

Completed

Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)

Japan
Eisai Co., Ltd.

Completed

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures (FYC01S)

Partial Seizures (With or Without Secondary Generalized Seizures) | Primary Generalized Tonic-clonic Seizures

Japan
Eisai Co., Ltd.

Completed

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures (FYC02T)

Partial Seizures (With or Without Secondary Generalized Seizures) | Primary Generalized Tonic-clonic Seizures

Japan
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

Epilepsy | Partial Seizures With or Without Secondary Generalization

Japan
Abbott
Abbott Japan Co.,Ltd

Completed

Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)

Hemodialysis | Secondary Hyperparathyroidism

Japan
Abbott

Completed

Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism

Hemodialysis | Secondary Hyperparathyroidism

Japan
Abbott
Abbott Japan Co.,Ltd

Completed

Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis

Secondary Hyperparathyroidism | Chronic Kidney Disease on Hemodialysis

Japan
Takeda

Completed

Phase III Study of Intramuscular TAK-816 in Healthy Infants

Healthy Volunteers | Haemophilus Influenzae Type b, Prevention

Japan
Bayer

Completed

Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease

Anti-Infective Agents

Japan
Bayer
Janssen Research & Development, LLC

Not yet recruiting

An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure

Children | Congenital Heart Disease | Prevention of Venous Thromboembolism | Fontan Procedure

Japan
National Center of Neurology and Psychiatry, Japan

Completed

Phase II Clinical Trial of OCH-NCNP1

Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary Progressive

Japan
AbbVie (prior sponsor, Abbott)

Completed

Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism

Hemodialysis | Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Mineral and Bone Disorders Outcomes in Stage 5D of Chronic Kidney Disease (MBD-5D)

End Stage Renal Disease | Hyperparathyroidism, Secondary

Japan
Novartis Pharmaceuticals

Completed

Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety (ZIPANGU)

Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Japan
Janssen Pharmaceutical K.K.

Terminated

A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants

Respiratory Syncytial Virus Prevention

Japan
AstraZeneca

Terminated

VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19

Prevention of Infectious Disease Caused by SARS-CoV-2

Japan
Navitas Life Sciences GmbH
GE Healthcare; Bayer; Guerbet

Completed

Long-Term Retention of Gadolinium in Bone

Focus: Long-term Retention of Gadolinium-based Contrast Agent

Spain, Korea, Republic of, United States, Germany, Japan, Turkey
Takeda

Completed

A Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Japan
UCB Biopharma SRL

Enrolling by invitation

A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

Epilepsy | Partial Seizures With or Without Secondary Generalization

China, Japan
AstraZeneca

Completed

VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA

Prevention of Infectious Disease Caused by SARS-CoV-2

Japan
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy

Epilepsy | Partial Seizures With or Without Secondary Generalization

China, Japan, Malaysia, Philippines, Singapore, Taiwan, Thailand
AstraZeneca

Completed

Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin

Prevention

Korea, Republic of, Japan, Taiwan
Novartis Pharmaceuticals

Completed

Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients

Secondary Progressive Multiple Sclerosis (SPMS)

Japan
Novartis Pharmaceuticals

Active, not recruiting

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

Relapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple Sclerosis

Japan
Pfizer

Completed

A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases

Acute Bronchitis

Japan
Sanofi

Active, not recruiting

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

Secondary Progressive Multiple Sclerosis

United States, Argentina, Belgium, Canada, Czechia, France, Germany, Greece, India, Israel, Netherlands, Norway, Portugal, Turkey, United Kingdom, Japan, Austria, Bulgaria, China, Denmark, Finland, Italy, Lithuania, Poland, Romania, Russian... and more
Novartis Pharmaceuticals

Completed

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Secondary Progressive Multiple Sclerosis

China, Germany, United States, Romania, Italy, Austria, Belgium, Czechia, Spain, Australia, Canada, France, Israel, Switzerland, Japan, Bulgaria, Netherlands, United Kingdom, Estonia, Latvia, Lithuania, Russian Federation, Turkey, Slo... and more
Bayer
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Macular Edema Secondary to Retinal Vein Occlusion

Japan, Korea, Republic of, China, Israel, Lithuania, United States, Italy, Spain, Hungary, Portugal, Serbia, Poland, United Kingdom, Thailand, Czechia, Austria, Germany, Turkey, Australia, Bulgaria, Estonia, France, Georgia, Latvia, Mal... and more
Biogen

Completed

A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (MOTION - JAPAN)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent Progressive

Japan
Bayer
Janssen Research & Development, LLC; Population Health Research Institute

Completed

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS)

Prevention & Control

Belgium, Finland, France, China, United States, Colombia, Ireland, Philippines, Japan, Hungary, Canada, Germany, Australia, Chile, Czechia, Korea, Republic of, Malaysia, Brazil, Denmark, Israel, Russian Federation, South Africa, Ecu... and more
Swedish Orphan Biovitrum

Recruiting

Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE (EMERALD)

Systemic Lupus Erythematosus | Macrophage Activation Syndrome | Still Disease | Secondary Hemophagocytic Lymphohistiocytosis | SJIA | AOSD | MAS

United States, Belgium, Italy, Netherlands, United Kingdom, China, France, Spain, Czechia, Canada, Sweden, Japan, Germany, Poland
Bayer

Terminated

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke (OCEANIC-AF)

Atrial Fibrillation | Prevention of Stroke or Systemic Embolism

Canada, United States, Israel, Korea, Republic of, China, Taiwan, Belgium, Australia, Singapore, Malaysia, Slovakia, United Kingdom, Czechia, Latvia, Japan, Brazil, Lithuania, Germany, France, Sweden, Turkey, Switzerland, Estonia, Bul... and more
Janssen Research & Development, LLC

Recruiting

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

United States, United Kingdom, Korea, Republic of, Taiwan, Canada, Denmark, France, Thailand, New Zealand, Spain, China, Israel, Germany, Colombia, India, Netherlands, Australia, Japan, Sweden, Czechia, Italy
Incyte Corporation

Recruiting

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER)

Myelofibrosis | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome | Relapsed or Refractory Primary Myelofibrosis | Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis) | ET...

United States, Spain, Japan, Italy, Finland, United Kingdom, Canada
Bayer

Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke (OCEANIC-STROKE)

Acute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic Attack

United States, Switzerland, Belgium, Sweden, Canada, Australia, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, Greece, Japan, Turkey, Netherlands, Romania, China, United Kingdom, Portugal, Italy, Brazil, France, Slovakia, ... and more

Clinical Trials on Secondary Prevention in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations